Due to the highly contagious nature of Omicron, many London boroughs are simply running out of covid testing kits.
Consequently it is great news today that Avacta said it's leading rapid lateral flow test (offering 98% sensitivity & 99% specificity) had received CE Mark approval for direct consumer use in the UK & EU.Meaning both Brits & Europeans can now buy these tests directly without having to obtain them from a 3rd parties such as the NHS, airlines, etc.
On top, many overseas countries are also struggling to obtain sufficient quantities of RLFTs, opening the international door to innovators like Avacta & its exclusive partner Medusa Healthcare.
CEO Alastair Smith, adding: "This is an extremely important step forwards in the commercialisation of [our "MeduFlow" RLFT]. As the pandemic progresses, the world is moving away from professional use tests [towards] self-testing kits.Our RLFT is the first UK product to receive a CE mark for self-testing which - coupled with the fact that it is based on innovative UK technology & is UK manufactured - are important selling points for customers in the UK, EU and elsewhere."
Watch this space.